OncoMatch/Clinical Trials/NCT06372717
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Is NCT06372717 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including APL-4098 and Azacitidine and APL-4098 for acute myeloid leukemia refractory.
Treatment: APL-4098 · Azacitidine and APL-4098 · Azacitidine and Venetoclax and APL-4098 — This is an open-label, Phase 1 study to determine the safety, tolerability, and efficacy of APL-4098 alone, and in combination with azacitidine, and in combination with azacitidine plus venetoclax for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS)/AML and MDS-excess blasts (EB).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic stem cell transplant
received an allogeneic stem cell transplant within 6 months of screening
Cannot have received: autologous stem cell transplant
received an autologous stem cell transplant within 3 months of screening
Cannot have received: anti-cancer treatments
received any anti-cancer treatments within 2 weeks of Cycle 1 Day 1
Cannot have received: radiation therapy
prior radiation therapy within 4 weeks of screening
Lab requirements
Blood counts
WBC count ≤ 25,000/microliter
Kidney function
calculated or measured creatinine clearance ≥ 45 mL/minute (multiply by 0.85 if female)
Liver function
Aspartate aminotransferase and/or alanine aminotransferase ≤ 3 x upper limit of normal (ULN), total bilirubin ≤ 1.5 x ULN
Cardiac function
Left ventricular ejection fraction ≥ 45%, Fridericia's corrected QT interval ≤ 470msec
WBC count ≤ 25,000/microliter; Left ventricular ejection fraction < 45%, Fridericia's corrected QT interval > 470msec, Aspartate aminotransferase and/or alanine aminotransferase > 3 x upper limit of normal (ULN), total bilirubin > 1.5 x ULN, calculated or measured creatinine clearance < 45 mL/minute (multiply by 0.85 if female)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06372717 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic stem cell transplant, autologous stem cell transplant, anti-cancer treatments disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify